Search

Regeneron Pharmaceuticals Inc

Cerrado

SectorSanidad

781.44 1.7

Resumen

Variación precio

24h

Actual

Mínimo

778.83

Máximo

785.74

Métricas clave

By Trading Economics

Ingresos

570M

1.3B

Ventas

685M

4.3B

P/B

Media del Sector

18.784

68.51

BPA

12.53

Rentabilidad por dividendo

0.48

Margen de beneficios

30.226

Empleados

15,410

EBITDA

576M

1.5B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+5.68% upside

Dividendos

By Acuity

Rentabilidad por dividendo

Media del Sector

0.48%

2.29%

Próximas Ganancias

27 oct 2026

Fecha Próximo Dividendo

31 ago 2026

Próxima Fecha de Ex Dividendo

18 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

8.2B

78B

Apertura anterior

779.74

Cierre anterior

781.44

Noticias sobre sentimiento de mercado

By Acuity

60%

40%

291 / 340 Clasificación en Healthcare

Regeneron Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ago 2026, 22:16 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and unlawful business practices.

6 ago 2026, 19:26 UTC

News
Social Media

Regeneron Pharmaceuticals faces a potential class action lawsuit over alleged securities fraud, contributing to a decline in shares despite receiving Health Canada approval for Libtayo.

5 ago 2026, 20:06 UTC

Regeneron Pharmaceuticals is trading higher, reflecting gains since Tuesday, amid a decline in crude oil prices that eases inflationary pressures.

4 ago 2026, 23:46 UTC

Regeneron Pharmaceuticals is roughly flat in after-market trading, remaining well above its 20-day moving average and near the upper end of its one-month range.

3 ago 2026, 19:46 UTC

News

Regeneron Pharmaceuticals faces class action lawsuits over alleged securities fraud related to its Phase III Fianlimab-Libtayo Study, contributing to lower share prices.

1 ago 2026, 00:01 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

31 jul 2026, 23:06 UTC

News

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

30 jul 2026, 19:49 UTC

Regeneron Pharmaceuticals is trading higher, significantly above its 20-day moving average and near the upper end of its one-month trading range.

29 jul 2026, 23:16 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining strength above the 20-day moving average despite broader market caution over rising interest rates.

28 jul 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc is higher in after-hours trading, continuing its positive momentum and remaining above its 20-day moving average. No specific news was identified.

27 jul 2026, 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining momentum with strong cumulative returns and three consecutive higher daily closes.

25 jul 2026, 00:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reaching the upper end of their one-month trading range. No specific news was identified.

24 jul 2026, 20:13 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, remaining near the upper end of their one-month range. No specific news was identified.

23 jul 2026, 09:56 UTC

Regeneron Pharmaceuticals Inc shares are modestly higher in pre-market trading. No specific company news was identified to explain the price movement.

22 jul 2026, 23:46 UTC

Regeneron Pharmaceuticals shares are higher in after-hours trading, peaking post-market despite cautious sentiment from rising crude oil prices and geopolitical tensions.

21 jul 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

17 jul 2026, 19:26 UTC

Social Media
News

Regeneron Pharmaceuticals faces a class action lawsuit from Levi & Korsinsky, LLP, contributing to ongoing declines in the stock amid market volatility.

16 jul 2026, 20:03 UTC

Regeneron Pharmaceuticals is trading higher, supported by gains in the Biotechnology sub-sector amid a strong broader market performance today.

15 jul 2026, 19:16 UTC

Regeneron Pharmaceuticals Inc shares are higher Wednesday, recovering from an earlier dip and remaining above the 20-day moving average. No specific news was identified.

13 jul 2026, 19:26 UTC

Regeneron Pharmaceuticals shares are lower today amid broader market declines driven by rising oil prices and geopolitical tensions. No specific company news was identified.

11 jul 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reflecting a notable gain near the upper end of its one-month trading range.

10 jul 2026, 19:26 UTC

Correlated Moves

Regeneron Pharmaceuticals Inc shares declined amid broader biotechnology sector pressures and geopolitical tensions, despite earlier reaching a session high before pulling back.

9 jul 2026, 23:51 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours following a weak trading session, despite a report showing a decrease in initial jobless claims.

8 jul 2026, 19:53 UTC

News

Regeneron Pharmaceuticals shares are lower, pressured by declines in the Biotechnology sector and a reduced price target of $730 from Morgan Stanley.

7 jul 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, supported by stable performance and positioning above the 20-day moving average.

6 jul 2026, 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline amid mixed market sentiment.

2 jul 2026, 23:26 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, despite a lower-than-expected jobs report easing rate hike fears and boosting sentiment for some risk assets.

1 jul 2026, 19:16 UTC

Regeneron Pharmaceuticals is trading higher, reflecting positive biotechnology sector performance. The stock remains above its 20-day moving average and near a one-month peak.

30 jun 2026, 23:16 UTC

Regeneron Pharmaceuticals shares remain roughly flat in after-market trading, following three consecutive sessions of declines and no specific news identified.

29 jun 2026, 23:06 UTC

News

Regeneron Pharmaceuticals will join the FDA's PreCheck Pilot Program to enhance domestic drug manufacturing. Shares are trading lower in after-market hours.

Comparación entre iguales

Cambio de precio

Regeneron Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

5.68% repunte

Estimación a 12 Meses

Media 828.95 USD  5.68%

Máximo 1,030 USD

Mínimo 641 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Regeneron Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

21 ratings

14

Comprar

7

Mantener

0

Vender

Sentimiento

By Acuity

291 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat